Astellas Bows Out Of Try For CV Therapeutics
This article was originally published in PharmAsia News
Astellas Pharma is canceling plans for a hostile takeover of U.S.-based CV Therapeutics. The decision followed an agreement by CV's board to accept the bid of Gilead Sciences. In addition to withdrawing from the acquisition bid, Astellas also said it would drop its court case that sought to challenge CV's efforts to block the Astellas bid. Astellas ended up bidding $4 per share less than Gilead for control of CV. (Click here for more
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.